All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @juliestollkelly on TikTok · 18s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @juliestollkelly's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Yeah, I forgot to take my NAD, my BPC-157 TB-500 last night.
  2. 0:05And so this morning I was like, I need to get up early and I need to take it.
  3. 0:11That's how much I love these peptides. They've literally changed my life.
  4. 0:15Take them, crawl back into bed.

@juliestollkelly's peptide injection video, fact-checked

Julie Freakin Kelly

TikTok creator

14.1K viewsWatch on TikTok

Quick answer

The creator is self-administering a stack of BPC-157, TB-500, and NAD via injection, compounds with preclinical and limited human data for tissue repair and cellular energy support. None of these are FDA-approved therapeutic agents, and their use exists in a compounding and research context without standardized clinical protocols. Patient-reported quality-of-life improvements are common in this space but have not been validated in controlled human trials for this specific combination.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @juliestollkelly's peptide injection video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@juliestollkelly's peptide injection video, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@juliestollkelly's peptide injection video, fact-checked" from Julie Freakin Kelly. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-administering a stack of BPC-157, TB-500, and NAD via injection, compounds with preclinical and limited human data for tissue repair and cellular energy support.

The reason this review is not generic is the source wording and the canonical claim label "peptides early morning injection." In this clip, the useful excerpt is: "Yeah, I forgot to take my NAD, my BPC-157 TB-500 last night." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

TB-500 is a synthetic fragment of Thymosin Beta-4.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-administering a stack of BPC-157, TB-500, and NAD via injection, compounds with preclinical and limited human data for tissue repair and cellular energy support.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-administering a stack of BPC-157, TB-500, and NAD via injection, compounds with preclinical and limited human data for tissue repair and cellular energy support. None of these are FDA-approved therapeutic agents, and their use exists in a compounding and research context without standardized clinical protocols. Patient-reported quality-of-life improvements are common in this space but have not been validated in controlled human trials for this specific combination.
  • BPC-157 has no FDA-approved human indication. Its evidence base is primarily rodent studies, including repeated work from Sikiric et al. in Current Pharmaceutical Design spanning two decades.
  • TB-500 is a synthetic fragment of Thymosin Beta-4. Goldstein et al. (2012, Annals of the New York Academy of Sciences) reviewed cardiac and wound healing applications, but human trial data remains limited.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • BPC-157 has no FDA-approved human indication. Its evidence base is primarily rodent studies, including repeated work from Sikiric et al. in Current Pharmaceutical Design spanning two decades.
  • TB-500 is a synthetic fragment of Thymosin Beta-4. Goldstein et al. (2012, Annals of the New York Academy of Sciences) reviewed cardiac and wound healing applications, but human trial data remains limited.
  • Injectable NAD is not equivalent to oral NMN or NR supplements. Bioavailability differences between delivery methods have not been standardized in human trials.
  • Compounded peptides sourced outside a licensed provider relationship carry real risks: contamination, mislabeling, and inconsistent dosing are documented concerns in the compounding industry.
  • The FDA has taken steps to restrict certain peptides including BPC-157 from bulk compounding. Legal access depends on current regulatory status in your jurisdiction.
  • Patient-reported outcomes in peptide communities are frequently positive, but self-selection, placebo response, and the absence of control conditions make these reports unreliable as evidence of efficacy.
  • Anyone using injectable peptides should do so under physician supervision with baseline and follow-up labs, not based on social media routines.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @juliestollkelly actually say?

She said she woke up early specifically to take her missed dose of NAD, BPC-157, and TB-500 because "they've literally changed my life." That's it. No specific health claims, no dosing details, just a strong personal endorsement and a routine injection before crawling back to bed.

To be fair, this is a lifestyle post, not a medical lecture. She's not claiming these peptides treat a disease or prescribing anything to her audience. But 14,000 viewers watching someone describe an urgent early-morning injection routine for compounds most of them have never heard of is not a neutral act. The implicit message is: these are worth your time, your money, and a needle.

Does the science back this up?

Partially, and with serious caveats. BPC-157 and TB-500 have real preclinical data behind them, but almost none of it comes from human trials. That gap matters more than most peptide enthusiasts admit.

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. Animal studies, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design, show accelerated tendon, muscle, and gut healing in rodents. TB-500 is a synthetic fragment of Thymosin Beta-4, which has shown pro-angiogenic and anti-inflammatory properties in animal and some cardiac surgery contexts (Goldstein et al., 2012, Annals of the New York Academy of Sciences). NAD precursors like NMN and NR have more human data, with Yoshino et al. (2021, Science) showing metabolic improvements in postmenopausal women, though injectable NAD specifically has a thinner evidence base.

The honest summary: promising animal data, weak human data, no FDA approval for any of these as therapeutics.

What did they get wrong (or right)?

She didn't technically get anything wrong because she didn't make a specific medical claim. What she got right, inadvertently, is that these compounds are being used widely in biohacking and recovery communities, and patient-reported outcomes are often positive. That's real, even if anecdote isn't evidence.

What she glossed over is significant. BPC-157 and TB-500 are not FDA-approved. They exist in a regulatory gray zone, available through compounding pharmacies under certain conditions or, less legitimately, through research chemical suppliers. The injection she's describing carries real risks: infection at the injection site, unknown long-term effects, batch-to-batch inconsistency in compounded products, and no standardized dosing established in humans.

Her framing, "that's how much I love these peptides," positions urgency around a missed dose of unapproved compounds. For a general audience, that framing can normalize something that warrants a lot more context than a TikTok allows.

What should you actually know?

If you're curious about peptide therapy, the conversation starts with a licensed provider, not a TikTok comment section. BPC-157 and TB-500 are being used clinically in some telehealth and sports medicine contexts, but the protocols vary widely because the human evidence base is thin enough that no consensus guidelines exist.

The regulatory picture is also shifting. The FDA has moved to restrict certain peptides from compounding, and what's available legally depends on your jurisdiction and how your provider sources the compounds. Compounded peptides are not the same as any brand-name approved drug, and quality control is a legitimate concern.

NAD has a longer human research trail than the two peptides here, with studies exploring its role in cellular energy metabolism and aging. But injectable NAD is not the same as oral NMN or NR, and the bioavailability comparisons are not settled science. Anyone stacking all three of these should be doing so under medical supervision with regular labs, not because someone on TikTok woke up early for their shot.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Julie Freakin Kelly · TikTok creator

14.1K views on this video

Early morning injection 😝

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about bpc-157 has no fda-approved human indication. its evidence base?

BPC-157 has no FDA-approved human indication. Its evidence base is primarily rodent studies, including repeated work from Sikiric et al. in Current Pharmaceutical Design spanning two decades.

What does the video say about tb-500?

TB-500 is a synthetic fragment of Thymosin Beta-4. Goldstein et al. (2012, Annals of the New York Academy of Sciences) reviewed cardiac and wound healing applications, but human trial data remains limited.

What does the video say about injectable nad?

Injectable NAD is not equivalent to oral NMN or NR supplements. Bioavailability differences between delivery methods have not been standardized in human trials.

What does the video say about compounded peptides sourced outside a licensed provider relationship carry real?

Compounded peptides sourced outside a licensed provider relationship carry real risks: contamination, mislabeling, and inconsistent dosing are documented concerns in the compounding industry.

What does the video say about the fda has taken steps to restrict certain peptides including?

The FDA has taken steps to restrict certain peptides including BPC-157 from bulk compounding. Legal access depends on current regulatory status in your jurisdiction.

What does the video say about patient-reported outcomes in peptide communities?

Patient-reported outcomes in peptide communities are frequently positive, but self-selection, placebo response, and the absence of control conditions make these reports unreliable as evidence of efficacy.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Julie Freakin Kelly, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.